Umbilical cord blood (UCB) transplantation is being used as an alternative source of hematopoietic stem cells for bone marrow reconstitution. Separation, processing and cry preservation of UCB samples in large numbers for storage in cord blood banks ideally needs to be partially automated to allow large numbers of samples to be processed efficiently. Aim of the present study was to carried out for standardization of collection, processing, cry preservation and quantification of CD34+ haematopoietic stem cells in umbilical cord blood. A total of 420 umbilical cord blood units were collected. Samples were analyzed for CD34+ cells concentration and viability of mononuclear cells were done on all the samples. The mean of the CD34+ cells concentration was 1.99± 0.82 % (range 0.4-4.5) on baseline period. The mean of the CD34+ cells concentration was 1.14± 0.85 % (range 0.2-3.8) on six month. The mean of the viability of mononuclear cells was 81.80 ±3.73℅ (range 76-91) on baseline period. The viability of mononuclear cells count at six month was 64.24± 2.70℅ (range 61-70). The viability loss of mononuclear cells from baseline to six month was 20.9℅. The mean of the total nucleated cells count was 11.36 ± 4.34 cells/ µl, (0.67- 16.68). In conclusion, the method demonstrates that UCB units can be routinely processed in a closed system that also achieves a significant reduction in storage needs and related costs, while maintaining quantity and quality of the haematopoitic stem cells.
Proteomics is emerging technology that is approach to the study of complete complement of protein, trnascriptomics and genomics disparity in large scale as a result of beneficial in drug discovery and development process. A handful of disease biomarker is at present worn usually for population screening disease identification, prediction, monitoring of therapy, and expect of therapeutic response. Unluckily, most of the biomarker goes through from low sensitivity, specificity, and prognostic value mainly to unusual disease in inhabitant’s transmission program. Require new disease biomarkers so as to will additional improve our ability to detect, prognoses, and predict therapeutic response in many types of disease. Novel biomarker discovery and drug target justification are highly complex and supply-rigorous processes, requiring an integral use of various tools, approaches and information. The newly developed proteomic technology features elevated-throughput similar examination of thousands of proteins in individual patients and amount populations and thus opens up the opportunity of given that more details at a global level on the molecular mechanisms. With frequently efficient public databases, bioinformatics can contribute to these processes by providing functional information of target candidates and correlating this information to the biological pathways. In this review, we summarize up to role of drug discovery date advance of bioinformatics application in proteomic research on biomarker discovery and drug target rationale. Particularly, we highlight how Proteomics in identification of new targets for drug discovery and new biomarkers for diagnosis and prognosis of diseases can facilitate the proteomic studies of biomarker identification and drug target validation.